

Anchen Pharmaceuticals, Inc. Its Past and Its Future

Chih-Ming Chen November 17, 2007



History

- Oct. 2002:
 - Founded in Irvine CA with the Goal of Developing Generic Controlled-Release Products (rented rooms in Stason)
- Mar. 2004:
 - Built its Own R&D Facility and Pilot Plant in Irvine California (26,000 SF)



Growth in Taiwan

- Sept. 2003 to now:
 - Worked Closely with Empax Pharma (英伯士) in Neihu, Taiwan
 - Followed by Acquisition of Empax
 - Purchased ex Parke Davis Plant in Chung-Li Industrial Zone
 - 70 plus Employees



Milestones in Taiwan

- **2006/2007:**
 - 3 ANDA's Filed in US from C-L plant
- July 2007:
 - Pre-Approval Inspection (PAI)
 - Zero 483 observations by US FDA
- **2007/2008:**
 - Preparing Production for Exporting Generic Drug Products to US



Growth in Irvine CA

- March 2006:
 - Built New Production Facility at Irvine, CA (45,000 SF) for Commercialization of Its First Product, Bupropion ER Tablets
 - 130 plus Employees



Milestones in Irvine CA

- Sept. 2004:
 - First ANDA (generic Wellbutrin XL) Filed as First-to-File (FTF) with Paragraph IV Certification and Triggered Law Suit by GSK
- Aug. 2006:
 - Won Law Suit and Granted 180-day Market Exclusivity



Milestones in Irvine CA

- Dec. 2006:
 - Received FDA Final Approval (after Citizen Petition was resolved)
 - Transferred Market Exclusivity of 300 mg
 Dose to Teva (manufactured by Impax)
- March 2007:
 - Settlement on 150 mg Strength (5 parties)
- June 2007:
 - Launched Anchen's 300 mg strength in June 2007 (on 181th day)



Milestones in Irvine CA

- Jan. 2006
- Filed Another FTF with Paragraph IV
 Certification, Generic Ambien CR 12.5 mg
- Citizen Petition by Sanofi
- 1Q 2009:
- Expect to Launch Generic Version of Ambien CR Tablets



Anchen's Future

- Annual Revenue Approx. \$75M, and Growing
- Expansions of Production Facilities in Chung-Li, Taiwan and Irvine, CA
- Investment in R&D for Both Generic and Brand Products



Anchen's Future

PRODUCT!

PRODUCT!

PRODUCT!



Anchen's Future

- Brand Products:
 - IP Protection
 - Sustainable/Growing Revenues
 - NDA Submissions
 - OCE (Old Chemical Entities)
 - NCE (New Chemical Entities)
 - Biotech Products